Above-label doses of octreotide-LAR in patients with metastatic small intestinal carcinoid tumors

Gastrointestinal Cancer Research

Volumn 6, Issue 3, 2013, Pages 81-85

  Strosberg, Jonathan ^a   Weber, Jill ^b   Feldman, Max ^b   Goldman, Jamie ^a   Almhanna, Khaldoun ^a   Kvols, Larry ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; CHROMOGRANIN A; OCTREOTIDE;

ADULT; AGED; ARTICLE; CARCINOID SYNDROME; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FLUSHING; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METASTASIS; RETROSPECTIVE STUDY; SMALL INTESTINE TUMOR; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 84881486924     PISSN: 19347820     EISSN: 19347987     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Erspamer V, Asero B: Identification of ente-ramine, the specific hormone of the enterochro-maffin cell system, as 5-hydroxytryptamine. Na-ture 169:800-801, 1952
2. Thorson A, Biorck G, Bjorkman G, et al: Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation with-out septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyano-sis: a clinical and pathologic syndrome. Am Heart J 47:795-817, 1954
3. Kvols LK, Reubi JC: Metastatic carcinoid tumors and the malignant carcinoid syndrome. Acta Oncol 32:197-201, 1993
4. Reichlin S: Somatostatin. N Engl J Med 309: 1495-1501, 1983
5. Lamberts SW, van der Lely AJ, de Herder WW, et al: Octreotide. N Engl J Med 334:246-254, 1996
6. Kvols LK, Moertel CG, O'Connell MJ: Treatment of the malignant carcinoid syndrome: evaluation of a long-acting somatostatin analogue. N Engl J Med 315:663-666, 1986
7. Rubin J, Ajani J, Schirmer W, et al: Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant car-cinoid syndrome. J Clin Oncol 17:600-606, 1999
8. Pritchard KI, Shepherd LE, Chapman JA, et al: Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA. J Clin Oncol 29:3869-3876, 2011
9. Anthony L, Stafford S, Cronin M: Octreotide LAR doses used in clinical practice: results from an internet survey and a clinical practice. Proc Am Soc Clin Oncol 22:3869-14S, 2004 (abstr 4274)
10. Kulke MH, Benson AB 3rd, Bergsland E, et al: Neuroendocrine tumors. J Natl Compr Canc Netw 10:724-764, 2012
11. Boudreaux JP, Klimstra DS, Hassan MM et al The NANETS consensus guideline for the diagnosis and management of neuroendo-crine tumors: well-differentiated neuroendo-crine tumors of the jejunum, ileum, appendix, and cecum. Pancreas 39:753-766, 2010
12. A study comparing treatment with 177Lu-DOTA0-Tyr3-octreotate to octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive midgut carcinoid tumours (NETTER-1). ClinicalTrials.gov identifier: NCT01578239, 2013